June 29, 2026 · Form 4 insider transaction
Dandekar Atul sold 7,500 shares of Maze Therapeutics, Inc. at $28.02 per share, a transaction worth $210.2K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.